Author
Listed:
- Christopher C. Nixon
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Maud Mavigner
(Emory University School of Medicine)
- Gavin C. Sampey
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Qura Therapeutics)
- Alyssa D. Brooks
(Emory University School of Medicine)
- Rae Ann Spagnuolo
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- David M. Irlbeck
(Qura Therapeutics
HIV Drug Discovery, ViiV Healthcare)
- Cameron Mattingly
(Emory University School of Medicine)
- Phong T. Ho
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Nils Schoof
(Emory University School of Medicine)
- Corinne G. Cammon
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Greg K. Tharp
(Emory University)
- Matthew Kanke
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Zhang Wang
(GlaxoSmithKline Research and Development)
- Rachel A. Cleary
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Amit A. Upadhyay
(Emory University)
- Chandrav De
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Saintedym R. Wills
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Qura Therapeutics)
- Shane D. Falcinelli
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Cristin Galardi
(Qura Therapeutics
HIV Drug Discovery, ViiV Healthcare)
- Hasse Walum
(Emory University)
- Nathaniel J. Schramm
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Jennifer Deutsch
(GlaxoSmithKline Research and Development)
- Jeffrey D. Lifson
(Frederick National Laboratory for Cancer Research)
- Christine M. Fennessey
(Frederick National Laboratory for Cancer Research)
- Brandon F. Keele
(Frederick National Laboratory for Cancer Research)
- Sherrie Jean
(Emory University)
- Sean Maguire
(GlaxoSmithKline Research and Development)
- Baolin Liao
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Guangzhou Medical University)
- Edward P. Browne
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Robert G. Ferris
(Qura Therapeutics
HIV Drug Discovery, ViiV Healthcare)
- Jessica H. Brehm
(Qura Therapeutics
HIV Drug Discovery, ViiV Healthcare)
- David Favre
(Qura Therapeutics
GlaxoSmithKline Research and Development)
- Thomas H. Vanderford
(Emory University)
- Steven E. Bosinger
(Emory University
Emory University School of Medicine)
- Corbin D. Jones
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Jean-Pierre Routy
(McGill University Health Centre
McGill University Health Centre)
- Nancie M. Archin
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- David M. Margolis
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Qura Therapeutics)
- Angela Wahl
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
- Richard M. Dunham
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
Qura Therapeutics)
- Guido Silvestri
(Emory University
Emory University School of Medicine)
- Ann Chahroudi
(Emory University School of Medicine
Emory University
Emory + Children’s Center for Childhood Infections and Vaccines)
- J. Victor Garcia
(University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill)
Abstract
Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy (ART). Estimates indicate that more than 70 years of continuous, fully suppressive ART are needed to eliminate the HIV reservoir1. Alternatively, induction of HIV from its latent state could accelerate the decrease in the reservoir, thus reducing the time to eradication. Previous attempts to reactivate latent HIV in preclinical animal models and in clinical trials have measured HIV induction in the peripheral blood with minimal focus on tissue reservoirs and have had limited effect2–9. Here we show that activation of the non-canonical NF-κB signalling pathway by AZD5582 results in the induction of HIV and SIV RNA expression in the blood and tissues of ART-suppressed bone-marrow–liver–thymus (BLT) humanized mice and rhesus macaques infected with HIV and SIV, respectively. Analysis of resting CD4+ T cells from tissues after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and robust induction of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, thymus, bone marrow, liver and lung. This promising approach to latency reversal—in combination with appropriate tools for systemic clearance of persistent HIV infection—greatly increases opportunities for HIV eradication.
Suggested Citation
Christopher C. Nixon & Maud Mavigner & Gavin C. Sampey & Alyssa D. Brooks & Rae Ann Spagnuolo & David M. Irlbeck & Cameron Mattingly & Phong T. Ho & Nils Schoof & Corinne G. Cammon & Greg K. Tharp & M, 2020.
"Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo,"
Nature, Nature, vol. 578(7793), pages 160-165, February.
Handle:
RePEc:nat:nature:v:578:y:2020:i:7793:d:10.1038_s41586-020-1951-3
DOI: 10.1038/s41586-020-1951-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Jinhee Kim & Deepanwita Bose & Mariluz Araínga & Muhammad R. Haque & Christine M. Fennessey & Rachel A. Caddell & Yanique Thomas & Douglas E. Ferrell & Syed Ali & Emanuelle Grody & Yogesh Goyal & Clau, 2024.
"TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo,"
Nature Communications, Nature, vol. 15(1), pages 1-17, December.
- Daniel B. Reeves & Christian Gaebler & Thiago Y. Oliveira & Michael J. Peluso & Joshua T. Schiffer & Lillian B. Cohn & Steven G. Deeks & Michel C. Nussenzweig, 2023.
"Impact of misclassified defective proviruses on HIV reservoir measurements,"
Nature Communications, Nature, vol. 14(1), pages 1-10, December.
- Wanwisa Promsote & Ling Xu & Jason Hataye & Giulia Fabozzi & Kylie March & Cassandra G. Almasri & Megan E. DeMouth & Sarah E. Lovelace & Chloe Adrienna Talana & Nicole A. Doria-Rose & Krisha McKee & S, 2023.
"Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections,"
Nature Communications, Nature, vol. 14(1), pages 1-13, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:578:y:2020:i:7793:d:10.1038_s41586-020-1951-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.